While pharmaceutical manufacturers' invoice prices remain at high levels as the reasonable zone diminishes, changes in their desired sales prices to hospitals suggest that they accept reductions in sales prices to the hospitals of some of their products, according to a study by the Ministry of Health's Pharmaceutical Affairs Bureau.
Quoted in Pharma Japan, the report says that invoice prices for 373 of 423 products (74.6%) were reduced following the reduction of their National Health Insurance prices last April, while invoice prices of 47 products were left unchanged, and those of three products increased.
The invoice/NHI price ratio has decreased for most products. The simple mean invoice price/NHI ratio was up by 2.7 percentage points since the NHI price revision. While the ratio was between 75% and 80% for 163 products (36%) before the NHI revision, it was between 80% and 85% for 245 products (49%) after the revision, indicating a tendency for invoice prices as a percentage of the NHI prices to increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze